Come see Kristine Nishida speak at the ISCT, International Society for Cell & Gene Therapy's annual meeting. You won't want to miss her poster either (Addressing Challenges in Potency Assay Development for CAR-T Products in Decentralized Manufacturing: A Case Study from Orgenesis MD) Session Details below: Roundtable Title: Enabling Point-of-Care Manufacturing: The Need to Improve QC Assays? ?? Roundtable Date: Wednesday, May 29, 2024? ?? Roundtable Time: 10:45 AM - 11:45 AM PT
Orgenesis Inc.
生物技术
Germantown，Maryland 6,779 位关注者
Unlocking the Potential of Cell and Gene Therapy for All (NASDAQ: ORGS)
关于我们
Orgenesis is a global biotech company that has been committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2012. Orgenesis established the POCare Network in 2020 to bring academia, hospitals, and Industry together to make these innovations more affordable and accessible to patients. In 2022, the POCare Services business unit responsible for developing and managing the decentralized POCare Centers and proprietary OMPULs was formed. Orgenesis will continue to focus on advancing to market through various partnerships its CGTs to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production.
- 网站
-
https://www.orgenesis.com
Orgenesis Inc.的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- Germantown，Maryland
- 类型
- 上市公司
- 创立
- 2012
地点
-
主要
获取路线
20271 Goldenrod Ln
US，Maryland，Germantown，20876
Orgenesis Inc.员工
动态
-
The Germfree and Orgenesis Inc. teams are in action, working to enable broader adoption of life-saving treatments and advance the field of cell and gene therapy! ?? Get the details on how Germfree and Orgenesis intend to transform the production of cell and gene therapies to make these vital treatments more affordable and accessible to patients worldwide. ?? https://hubs.ly/Q02wlwrH0 #CellandGeneTherapy #DecentralizedManufacturing #CGT #PatientAccess
-
-
In case you missed it yesterday, learn more about our exciting #cellandgenetherapy #collaboration with Germfree below: Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global #Accessibility https://lnkd.in/eiW_Gb5u
-
Thank you again to Cambridge Healthtech Institute, Brian Caine and all of his wonderful colleagues for organizing this fantastic event. Our CEO Vered Caplan is always eager and excited to discuss the merits of decentralized manufacturing for #celltherapy #CHIBioprocessingSummitEurope
Manager, Strategic Partnerships - Cambridge Venture, Innovation & Partnering Event Series
Amazing first day of #celltherapy #CMC #Analytics at the #CHIBioprocessingSummitEurope conference. Shout out to Angela Osborne for chairing the #celltherapy #manufacturing session featuring presentations from Chris Baldwin Vered Caplan Stephen Judd CEng MIChemE FIEI Kathryn Golden Lee Buckler Sarah Snykers Joaquim Vives Chris Crowell, Ph.D., leading to a terrific panel discussion on centralized vs. decentralized manufacturing strategies and a fireside chat Chris and Lee focusing on the next chapter to be written in commercializing cell therapies.
-
-
The close of 2023 is upon us, but we have one more opportunity to hear Sagi Nahum speak about leveraging analytics to enable #manufacturing #decentralization for #cellandgenetherapies. Don't miss him tomorrow at 4pm CET during the Informa #CellGene Therapy Manufacturing & Commercialization event in Dublin:
Agenda - Main Conference - Day 2 | Cell & Gene Therapy Manufacturing & Commercialization Europe
informaconnect.com
-
Today's the day! Our own Vered Caplan will be part of the ISPE Expert Xchange at 10:30am EST on Distributed & #Decentralized #Manufacturing for #cellandgenetherapies. Let's keep moving the conversation forward as an industry to change patient lives.
ISPE Expert Xchange: Distributed & Decentralised Manufacturing – Moving the Conversation Forward
ispe.org
-
"In theory, PoC #manufacturing makes sense. But in practice, it raises important questions, such as how #biopharma companies and #hospitals will work together to ensure product quality, process control, and regulatory compliance at each PoC site." Loved the point of care #cellandgenetherapy manufacturing discussion from Kerim Ozbilge, Ed Sullivan, and Brian Gavin of the EY Parthenon group in Cell & Gene. Also, we have answers to all those questions! Reach out any time for a chat.
Will Point-Of-Care Manufacturing Unlock The Value Of Autologous Cell Therapies?
cellandgene.com